Overview

• Combined rapamycin and trametinib treatment increased median survival by about 27% in male mice and 35% in females and yielded comparable gains in maximum lifespan.
• The regimen attenuated chronic inflammation in the brain, kidney, spleen and muscle while slowing the development of liver and spleen tumors in aged mice.
• Analysis of multiple tissues revealed that the dual therapy triggers distinct transcriptional shifts not seen with either drug alone.
• Both drugs already hold cancer therapy approvals, positioning the pairing for accelerated testing as a geroprotective intervention.
• Investigators are focusing on optimising trametinib dosing and delivery methods to ensure safety and efficacy ahead of planned human clinical trials.